Although much work has been done on clinical aspects of Burkitt's lymphoma, and intense interest has been shown in the relatively high rate of remissions and even "cures" among patients with this disease, there has been little analysis of longterm survival. The major reason for this has been the apparently enormous and seemingly insurmountable problems of keeping track of patients in the developing countries of Africa.
Clifford, working in Kenyatta National Hospital, Nairobi, Kenya, has been able to circumvent this problem to a very large extent by keeping patients in hospital for extended periods, and to date his series (Clifford, 1966 ; Pike, 1966) is the only major one in which complete survival information on the vast majority of patients is available.
Ideas on survival of patients attending Mulago Hospital, Kampala, Uganda, have been based on those known to have died plus those who continued to return to the follow-up clinic, but the fate of upwards of 50% of the patients leaving the hospital has not been known (Burkitt et al., 1965; Burkitt, 1966) . However, by combining the data gathered by Mr. D. Burkitt and Mr. A. Lubega (the Kampala Cancer Registry social worker) with the data we have ourselves collected since November 1966 it has been possible to obtain survival information on 74 of the 801 patients in a defined subpopulation of cases attending Mulago Hospital. This paper reports our findings in this group.
Clinical Material
The present study comprises the 80 patients diagnosed (microscopically, clinically, or parents before biopsy or treatment and died at home the same day; the other (Case J152), a 9-year-old boy with all four quadrants of the jaw involved, was taken home by his parents after biopsy but before treatment. His parents stated that they then took him to the local traditional medical practitioner, after which he had a full remission, but the disease later recurred and he died 585 days after his initial presentation at Mulago. The remaining 55 patients had specific treatment for their disease.
All of these treated patients received some form of chemotherapy. The most frequently used first drug was cyclo- The most important determinant of survival in this series appears to be the extent of the disease on first admission (see Fig. 2 and Table III It would clearly be extremely useful if on the basis of this series we could make some assessment of the relative efficacy of different chemotherapeutic regimens. However, as the extent of the disease at presentation appears to have a critical prognostic value, we need to compare different drugs (and different drug schedules) within a single staging category. Table IV shows that this is possible only with stage 3 cases; and Fig. 5 shows, within this staging division, the comparison of initial treatment with cyclophosphamide against all other drugs. For the first few months the patients receiving cyclophosphamide do better, but this advantage is not maintained. Younger patients did better than older patients (see Fig. 3 ). However, the age of the patient and the extent of his disease at presentation are highly interrelated (see Table II ), and it is not possible with this limited number of cases to separate them completely satisfactorily. Fig. 4 shows that among stage 3 cases age is apparently irrelevant, though there is a hint of better prognosis for the younger patients with stage 2 disease. If attention is restricted to patients under 10 years of age it is clear from 
Long-term Survivors
Ten of the 11 long-term survivors were under the age of 7 at presentation ; while their sex ratio (seven males, four females) is identical to that of all treated cases.
Two important points arise from a study of the treatment of these 11 patients. The first is the apparent value of surgery in some cases. All three survivors with stage 3 disease had extensive surgical excision of their tumour-two had bilateral ovariectomies and one had a tumour mass that involved the bladder, right ureter, and ileum removed. Though there was possibly abdominal tumour remaining in all three patients, the bulk of it is excised. Two of these patients also had jaw or orbit involvement, but surgical excision was never attempted at these sites. An orchidectomy, first of the right testis and two and a half years later of the left, was performed on one stage 1 survivor (Case K99). Altogether seven patients had surgery with removal of most of the tumour mass, and four of these are long-term survivors.
The second point is that four of the survivors (all stage 1 cases) had recurrences. One of these patients was the testicular tumour case referred to in the previous paragraph. All of the remaining recurrences were in a site clearly different from the original one. These four patients all had complete clinical remissions followed by recurrences from 22 to 80 weeks later.
Their recurrences were all still classifiable as stage 1.
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Discharged " Improved " To decide whether a patient has had a full or partial remission, or neither, is difficult in the best of circumstances. It is particularly so when these decisions have to be made retrospectively on the basis of case notes alone. We have nevertheless attempted this, and a certain amount of useful information was obtained. Mulago Hospital notes invariably stated for each discharged patient whether " improved " or " not improved," and we have accepted this dichotomous definition of remission as the best we could manage-we have thus taken " improved " to mean "in remission " except when the notes also showed that the patient still had " significant " residual tumour (this was not always easy to decide). Of the 24 patients discharged improved who subsequently had recurrences 10 did not bother to return to Mulago Hospital -two of these were stage 2 and the others stage 3 cases. The length of time between the discharge of these patients and death are (in days): 51, 63, 88, 124, 133, 162, 240, 285, 307, and 391 . It is surprising that these patients did not think it worth their while to return, in particular those with lengthy remissions.
Discussion
In this series the stage of the disease at presentation was of critical prognostic importance. However, as is well known to anyone working with this tumour, the disease does not invariably progress This, however, is all very speculative, and the major problems of which drug to give, the best total dose (of a particular drug) to give, and whether this should depend on the "extent" of the disease, remain unresolved. It is our belief that these problems will not be resolved without 
